

SCHEDULE 2 – THE SERVICES

1. **Service Specifications**

|  |  |
| --- | --- |
| **Service Specification No:** | 1719 |
| **Service** | Gender Identity Services for Adults (Non-Surgical Interventions) |
| **Commissioner Lead** | *For local completion* |
| **Provider Lead** | *For local completion* |

|  |
| --- |
| **Scope** |
| **Prescribed Specialised Service**1. This service specification covers the provision of non-surgical Gender Identity Services for adults that are prescribed as specialised services. This document should be read in conjunction with NHS England’s service specification for Gender Identity Services for Adults (Surgical Interventions).

**Description**1. Gender identity services includes specialist assessment, non-surgical care packages, certain surgical interventions and immediate associated after care provided by specialist centres.

**How the Service is Differentiated from Services Falling within the****Responsibilities of Other Commissioners**1. Integrated Care Systems are responsible for commissioning certain non-specialist elements of the NHS pathway of care for individuals with gender dysphoria.
 |
| **Care Pathway and Clinical Dependencies** |
| **Background****Gender dysphoria**1. The term used to describe a discrepancy between birth-assigned sex and gender identity is **gender incongruence**; this term is preferable to the formerly-used terms of gender identity disorder and transsexualism. Gender incongruence is frequently, but not universally, accompanied by the symptom of **gender dysphoria**.

 1. The current version of the International Statistical Classification of Diseases and Related Health Problems identifies ‘transsexualism’ (ICD 10 code F64) as “*a disorder characterized by a strong and persistent cross-gender identification (such as stating a desire to be the other sex or frequently passing as the other sex) coupled with persistent discomfort with his or her sex (manifested in adults, for example, as a preoccupation with altering primary and secondary sex characteristics through hormonal manipulation or surgery)*”.[[1]](#footnote-1)

**Extension of the model of care to primary care settings and sexual health settings**1. Subject to the outcome of early adopter evaluation NHS England may extend the model for delivery of care to multi-disciplinary teams based in primary care settings and sexual health settings, on a phased basis.

**Principles guiding the development of this service specification**1. Gender dysphoria is not, in itself, a mental health condition, reflecting contemporary professional opinion (Diagnostic and Statistical Manual of Mental Disorders (v5, 2013)).
2. It is optimal for the individual to be referred by their General Practitioner (GP) in view of the benefits of ongoing support by the GP, particularly after discharge from the specialist team. However, individuals may self-refer should they choose to do so.
3. Providers will respect the right of an individual to self-refer. These individuals should not be disadvantaged by a Provider’s insistence on obtaining a prescriptive set of data from the individual’s GP as a pre-condition to assessment as this may, in practice, deny an individual the right of self-referral.
4. All eligible individuals referred to a Gender Dysphoria Clinic may exercise full personal autonomy in respect of their gender identity and presentation; and must have equitable access to the range of interventions described in this service specification. Equity of access and high quality care will be provided to all individuals who meet the criteria for access to the NHS pathway of care. Each individual will receive timely and appropriate treatment, as a minimum in accordance with national waiting time requirements**.**
5. Assessments and interventions will be personalised and based on shared decision making, with service flexibility and reasonable adjustments to delivery of care to match the individual’s needs and circumstances.

**Designated Gender Dysphoria Clinics will:**1. Provide a high quality service for adults who have gender dysphoria; and will promote respect, dignity and equality for trans people.
2. Provide a timely and sustainable service for adults with gender dysphoria that meets the needs of the population, and incorporates the views of individuals**.**
3. Work with specialised services for gender variant adolescents and young people to ensure a timely and effective transfer to adult services**.**
4. Achieve an integrated approach to care with primary care providers and ensure close links with other expert centres at national and international levels**.**
5. Ensure timely and appropriate communications with services who are expected to provide other parts of the individual’s pathway.
6. Increase awareness of best practice in the diagnosis and management of gender dysphoria through active engagement with health professionals; and educate healthcare professionals in the health and support needs of trans people**.**
7. Collaborate in national and international research projects to increase the evidence base for the commissioning and delivery of specialised services for trans people**.**
8. Provide support, advice, expertise and training for the local, regional and national network**.**
9. Collaborate in sharing best practice, peer review, benchmarking, and in the development of research and innovation.
10. Employ consistent and equitable decision-making about the effective use of resources on the NHS pathway of care for trans people.
11. Publicise national and local patient organisations, which can provide invaluable additional information and ongoing support for trans people and their families.

**Staffing, structure and governance**Each Provider will have:1. A nominated Senior Clinical Lead, who has the key leadership role for the service overall. The Senior Clinical Lead must demonstrate evidence of appropriate experience and expertise in specialised gender dysphoria practice; significant management experience; and significant evidence of continued professional development.
2. A specialist multi-disciplinary team of professionals, with a mix of skills, experience and expertise that is appropriate to ensure the delivery of effective and high-quality services in accordance with the requirements of this service specification. The multi-disciplinary team will have the following competencies:
* Comprehensive mastery of clinical aspects of gender identity development and expression, formulation and diagnosis of gender identity-related bio-psycho-social concerns, and the management of gender dysphoria
* Expertise in sex development, and endocrine intervention in the treatment of gender identity-related bio-psycho-social concerns and gender dysphoria
* Expertise in physical health care needs that are specific to individuals with gender dysphoria
* Expertise in mental health care needs that are specific to individuals with gender dysphoria
* Expertise in social inclusion and care needs that are specific to individuals with gender dysphoria
* Expertise in gender-specific voice and communication development
* Good professional knowledge of specific psychological therapy, as relevant to the care of a trans and gender-diverse population
* Good professional knowledge of neuro-developmental conditions, including autism spectrum condition, and of adjustments to facilitate optimal communication with affected people
* Good professional knowledge of trichology
* Good professional knowledge of the care needs of individuals who are receiving specialised gender-related surgical procedures
1. A robust system of clinical governance that ensures, *inter alia*, all clinical staff are trained in meeting the health needs of trans people, and deemed competent to deliver the interventions as per their role.
2. A robust system of corporate governance, including a nominated senior manager, that demonstrates effective management, guidance, oversight and accountability by the host organisation (Board level or equivalent)**.**
3. Arrangements in place to ensure that the service delivers culturally appropriate care and support; individuals must be able to access services in a way that ensures their cultural, language and communication needs do not prevent them receiving the same quality of healthcare as others**.**
4. Sufficient administrative and managerial support needed for efficient and timely delivery of services**.**
5. Information and technology systems that enable patient contact remotely (such as video and web consultations) where this is appropriate to the individual’s circumstances; and the effective submission of data, including the reporting requirements of the national Referral to Treatment waiting time standards.
6. Premises that are appropriate to ensure effective delivery of the services described in this service specification; and in an environment that service users regard as safe and welcoming**.**
7. Arrangements in place (including ongoing training) to ensure that all staff in public-facing roles have cultural sensitivity towards trans and gender diverse people’s health and social care needs**.**
8. Arrangements in place to ensure that service improvement is shaped by active service user involvement, and be able to demonstrate how this is achieved via means that are accessible, transparent and inclusive.
9. Arrangements in place to ensure that complaints by service users are acknowledged investigated and responded to promptly; and that the means to complain are publicised and accessible.
10. Systems that demonstrate how Providers use audit, data management and analysis, service reviews (including peer reviews) and other intelligence to evaluate effectiveness and drive ongoing service improvement

**Care Pathway**1. The delivery model relies on access to specialist Gender Dysphoria Clinics usually via primary care, and the principle of multidisciplinary and interdisciplinary teams and networks who work and collaborate in the provision of care. Gender Dysphoria Clinics assess and diagnose individuals; directly provide some interventions and arrange for referrals to other services, including for medical and surgical treatments. Access to surgical intervention is only by referral from a specialist Gender Dysphoria Clinic that is commissioned by NHS England compliant with this specification. Some elements of the NHS care pathway are delivered by non-specialised services. A diagram of the pathway is at Appendix A.
2. The NHS pathway of care may be summarised as:
* Referral to a specialist Gender Dysphoria Clinic (self-referral; or by primary, secondary or tertiary care)
* Assessment for gender dysphoria, and diagnosis
* Individuals who meet the criteria for diagnosis of gender dysphoria related to gender incongruence are accepted on to the NHS care pathway and an individualised treatment plan is agreed
* Therapeutic interventions delivered by the specialist Gender Dysphoria Clinic; and / or referral for interventions with other providers
* Ongoing review and monitoring during and after interventions
* Conclusion of contact: discharge to primary care

**New referrals**1. Self-referrals may be made by individuals themselves, provided the individual is registered with a General Practitioner (GP). Referrals may also be made by GPs, other medically qualified professionals, and other professionals regulated by the *Health and Care Professions Council*. See Appendix B.

**Requests for transfers of care from specialised adult services**1. Transfers of care may be requested by other designated Gender Dysphoria Clinics. See Appendix C.

**Requests for transfers of care from the Gender Identity Development Service for Children and Young People**1. A request for transfer of care may be made by the designated Gender Identity Development Service for children and young people to a designated Gender Dysphoria Clinic before the young person’s 17th birthday. This may be appropriate where joint working between the two services, including joint consultations with the young person, within a “lead-in” period is beneficial to ensure a timely and effective eventual transfer once the young person has reached 17 years. See Appendix D.

**Assessment process for newly-referred individuals**1. The Provider will undertake a specialised assessment for people who may have gender dysphoria; work with them to identify the most appropriate diagnostic coding; and agree a treatment plan. If the diagnosis is that the individual does not have gender dysphoria as a consequence of gender incongruence, the Provider will advise the individual and referrer on alternative services that might meet the individual’s health and well-being needs. See Appendix E.

**Physical examination**1. Physical examination, other than the measurement of height, weight and blood pressure, must not be performed routinely during the assessment process. See Appendix F.

**Named professional’s role in treatment process**1. Individuals who progress to a treatment process, and individuals accepted for direct transfer of care between specialised services, will be allocated a ‘Named Professional’ for the duration of the episode of care. This will be a regulated health professional who will act as the individual’s primary ‘point of contact’ with the service, provide basic information about interventions and the care process, and oversee and facilitate timely progress through the individual’s treatment plan, including those elements of the care pathway that are delivered by other providers. See Appendix G.

**Lead Clinician role in treatment process**1. A registered medical practitioner or clinical or counselling psychologist will be appointed as ‘Lead Clinician’ for individuals who progress to a planned intervention on the NHS care pathway. See Appendix H.

**Shared decision making**1. Shared Decision Making is a process in which individuals, when they reach a decision point in their health care, can review all the treatment options available to them and participate actively with their healthcare professional in making that decision. The Named Professional and Lead Clinician will provide individuals with the necessary information about all of the options available to them so that they may ask questions, explore the options available, and take an active role in determining a treatment route which best suits their needs and preferences, and is clinically appropriate.

**Capacity and informed consent**1. The Named Professional and Lead Clinician must make all efforts to ensure that individuals are aware of the longer-term consequences of the interventions offered to them. The consequences of treatment decisions can be significant and life-changing.
2. The process of obtaining informed consent is an important aspect of ethical assessment and intervention, including the emotional, social and factual issues, so as to enable the individual to make informed decisions about the treatment options, benefits, material risks, and the alternatives to the treatments proposed (including the option of having no treatment). Individuals must be given sufficient time to reflect on the clinical advice and the potential treatment options before deciding what is best for them. Clinicians should be mindful that it is possible that individuals may lack capacity.

**Loss of fertility**1. The individual must be provided with early advice about the likely impact of medical interventions to physical health. Where loss of fertility is likely the Provider will provide a general description of the options for conservation of reproductive potential, and, where appropriate and with the individual’s consent, make a recommendation to the GP that they consider a referral to a fertility service for cryopreservation of eggs or sperm for use in future fertility treatment (gamete storage).
2. NHS England is not the responsible commissioner for gamete storage. An individual’s eligibility for NHS-funded gamete storage is determined in each case by the individual’s Integrated Care System.

**The Provider’s role in the treatment process**1. Individuals on the gender dysphoria pathway will have different needs, and the pathway will not always be linear or sequential. The Provider will be flexible and adaptable in matching the type, timing and order of interventions, and the duration of the entire treatment episode.
2. Individuals returning for treatment after a planned deferral will have a single ‘re-engagement’ consultation with the Lead Clinician but will not be fully re-assessed unless there are compelling clinical reasons to do this (these must be carefully explained to the patient).

**Interventions that are delivered directly by the Provider**1. ***Voice and Communication Therapy***
2. Each Provider must ensure access to an appropriate level of provision of specialist voice and communication therapy on the basis of clinical need and individual choice[[2]](#footnote-2). The number and frequency of sessions will be variable depending on the individual’s needs, and is likely to comprise a combination of individual and group therapy sessions.
3. The objective of therapy is to facilitate changes in the individual’s voice and communicative profile thereby improving quality of life and alleviating distress related to gender dysphoria. In less complex cases it may be appropriate for voice and communication interventions to be provided by appropriately-supported, non-specialist, local speech and language services (commissioned by the individual’s Integrated Care System) following a referral by the Provider. Any pre-existing voice difficulty that would impede successful specialist voice modification should first be treated by local speech and language therapy services (for which commissioning responsibility rests with Integrated Care Systems).
4. ***Specialised psychological interventions***
5. The Provider will make available specific psychological interventions that are adapted to the needs of the individual based on psychological assessment and collaborative formulation. Psychological interventions will not be offered routinely or considered mandatory, but instead with the consent of the individual and focussed on specific psychological needs. Other evidence-based psychological therapies for couples or groups may be offered if, based on psychological assessment and collaborative formulation, they meet the needs of the individual engaged in this care pathway. See Appendix I.

***Conversion therapy***1. Providers will not deliver, promote or refer individuals to any form of conversion therapy. The practice of conversion therapy is unethical and potentially harmful. For the purposes of this document ’conversion therapy’ is an umbrella term for a therapeutic approach, or any model or individual viewpoint that demonstrates an assumption that any gender identity is inherently preferable to any other, and which attempts to bring about a change of gender identity, or seeks to supress an individual’s expression of gender identity on that basis[[3]](#footnote-3).
2. ***Assessment for endocrine and other pharmacological interventions***
3. The Provider will assess an individual’s suitability for hormone treatments for the alleviation of gender dysphoria. Appendix J of this document describes arrangements for prescribing and monitoring of endocrine treatments.

**Interventions delivered by other providers**1. The Provider may refer the individual for other interventions delivered by other providers should the intervention be routinely commissioned by the NHS.

**Surgery for the treatment of gender dysphoria**1. This section should be read in conjunction with NHS England’s service specification for “*Gender Identity Services (Surgical Interventions)”* which describes the specialist surgical procedures that are commissioned by NHS England for the treatment of gender dysphoria.
2. The Provider may refer an individual for a surgical intervention that is commissioned by NHS England as a prescribed specialised intervention. Before a referral for surgery is made, the Lead Clinician will meet with the individual to review current treatment interventions, and to assess the individual’s needs and readiness for the surgical intervention. The processes of shared decision making and of obtaining consent (as described earlier in this document) will provide the individual with necessary information, and will allow the individual sufficient time to ask questions, and to reflect on the advice of the Lead Clinician to enable an informed decision on the treatment options, risks and benefits. The possibility of the need for donor site skin epilation for some patients, and the likely implications for the timing of surgery, should be explained to the individual at this stage.
3. A referral for mastectomy and reconstruction of the chest requires one letter of referral from a Lead Clinician.
4. Subject to the bullet point below, a referral for genital surgery requires two letters of referral: one from a Lead Clinician, the other from a similarly-qualified and experienced professional not directly involved in the individual’s care and able to form an independent opinion; at least one letter of referral must be from a Registered Medical Practitioner with expertise in gender dysphoria.The letters of referral for genital surgery will confirm:
5. Evidence of 12 continuous months of hormone therapy as appropriate to the individual’s gender goals (unless the individual has a medical contraindication or is otherwise unable or unwilling to take hormones)
6. Evidence of 12 continuous months of living in a gender role that is congruent with their gender identity; this must not entail a requirement for the individual to conform to externally imposed or arbitrary preconceptions about gender identity and presentation; this requirement is not about qualifying for surgery, but rather preparing and supporting the individual to cope with the profound personal and social consequences of surgery. Where individuals can demonstrate that they have been living in their gender role before the referral to the Provider, this will be taken into account
7. If an individual has been granted a Gender Recognition Certificate (GRC), as an outcome of the process described in the Gender Recognition Act 2004 they will have had a diagnosis of gender dysphoria; and will, at the time their GRC was granted, have lived fully for the previous two years in their acquired gender and continued to do so; and they will have intended to live permanently in their acquired gender. This information is confirmed in a written report of a medical practitioner (with a licence to practise) or psychologist on the List of Specialists in the Field of Gender Dysphoria maintained by HM Courts and Tribunal Service. Such individuals are eligible for a referral for genital surgery subject to a single opinion from a Registered Medical Practitioner who has knowledge of the individual’s care plan, and on the basis of informed consent[[4]](#footnote-4).
8. Hysterectomy (removal of uterus), bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes), penectomy (removal of penis) and orchidectomy (removal of testes) are interventions commissioned under this service specification when they are performed in conjunction with the above pathways by a specialist Gender Dysphoria surgical unit (described above). They are not commissioned by NHS England when they are performed as “stand alone” procedures; in such cases commissioning responsibility rests with the individual’s Integrated Care System.

**Conclusion of contact with the Provider**1. Individuals will be discharged from the care of the Provider:
* At an individual’s request
* When the individual and Lead Clinician agree that treatment for gender dysphoria is complete, and not less than six months after completion of the last planned intervention (the purpose of such follow-up is to assess the longer-term impact of interventions)
* In accordance with the Provider’s access policy
1. At discharge the Lead Clinician will provide advice to the individual’s GP on long-term health maintenance and screening.

**Interdependence with other Services**1. Each Provider’s Multi-Disciplinary Team will have access to the following expertise:
* Expertise in reproductive and sexual health, as relevant to the care of a trans and gender-diverse population
* Expertise in the care of people with severe mental illness, and competency to recommend reasonable adjustments in gender-related treatment planning for affected people
* Expertise in the care of people with learning disability and other special needs, including Autistic Spectrum Conditions and Attention Deficit Hyperactivity Disorder, and competency to recommend reasonable adjustments in gender-related treatment planning for affected people
* Expertise in Forensic Psychiatry or Forensic Psychology, and competency to recommend reasonable adjustments in gender-related treatment planning for affected people
* Expertise in the care of people with severe physical illness and disabilities, including complex endocrine disorders, and competency to recommend reasonable adjustments in gender-related treatment planning for affected people.

**Gender Identity Healthcare Credential (Royal College of Physicians)**1. The Gender Identity Healthcare Credential is for statutorily regulated healthcare professionals from any relevant profession who work with, or seeks to work with, adults who may need gender identity healthcare. Each Provider shall make arrangements to support practicum modules that offer work-based supervision and assessment of professionals undertaking the programme of study. These arrangements will be agreed between each Provider, NHS England, the Royal College of Physicians and relevant academic partners via an annual planning cycle.
 |
| 1. **Population Covered and Population Needs**
 |
| **Population Covered By This Specification**1. The service outlined in this specification is for patients ordinarily resident in England; or otherwise the commissioning responsibility of the NHS in England (as defined in guidance for “Establishing the Responsible Commissioner” and other Department of Health guidance relating to patients entitled to NHS care or exempt from charges). For the purposes of commissioning health services, this excludes patients who, whilst resident in England, are registered with a GP practice in Wales, but includes patients resident in Wales who are registered with a GP practice in England.
2. The Provider will receive referrals of individuals from 17 years of age who may have gender dysphoria that is a consequence of their gender identity being incongruent with their visible sex characteristics and/or the social role typically associated with those characteristics (gender incongruence). Subsequent interventions will only be accessed by individuals who have been diagnosed with gender dysphoria.
3. This specification recognises and respects diversity in gender identity and its expression. It recognises that there are other identities than the traditional (binary) identities associated with ‘man’ and ‘woman’, and that gender diverse people with such identities (and who are known by a variety of other names, including non-binary, trans-feminine, trans-masculine, Genderqueer, non-gender and others) who meet the criteria for access to the NHS pathway of care must have access to treatment and the interventions described in this document that is equitable to the access available to people with binary identities.

Exclusions1. Referrals will not be accepted for individuals who are not registered with a GP given the benefits to the individual of ongoing support from their GP, particularly after discharge from the care of the specialist team.

**Population needs; and Expected Demographic Changes**1. There is no official data on the number of people in England who present with a degree of gender variance. Difficulties in assessing prevalence are exacerbated by the limited evidence base. There is considerable variation in reported prevalence due to factors such as: variable data reporting by providers; differences in diagnostic thresholds applied and inconsistent terminology; the methodology and diagnostic classification used; and the year and country in which the studies took place. Thus there is considerable variation in estimates, and the absence of reliable prevalence data exacerbates the challenges in planning and commissioning gender identity services. What is consistent across the literature is a recognition that the number of people pursuing treatment options – the incidence of expressed need - is rising significantly
 |
|  |

**Appendix A**







**Appendix B: New Referrals**

All Providers designated against this service specification will operate in accordance with a nationally-consistent access policy.

Referrals may be made by individuals themselves; General Practitioners (GP); other medically qualified professionals; and other professionals regulated by the Health and Care Professions Council. The Provider will acknowledge the referral in writing with the referrer and individual within 14 days.

Providers will respect the right of an individual to self-refer. These individuals should not be disadvantaged by a Provider’s insistence on obtaining a prescriptive set of data from the individual’s GP as a pre-condition to assessment as this may, in practice, deny an individual the right of self-referral.

Providers will not be unnecessarily prescriptive about the information to be included with the referrals (including insistence on use of template forms) but referrers will be encouraged to provide the following information:

* A description of the individual’s experience of gender dysphoria, including duration
* The individual’s clinical needs and expectations
* A summary of significant physical and mental health history
* History of substance misuse
* Risk assessment
* Forensic history
* Development history
* Information regarding and copies of correspondence related to any previous care for gender dysphoria
* The individual’s current medication use (prescribed; self-medication; recreational)
* Significant social history
* Basic biometrics (height; weight; Body Mass Index; blood pressure)

**Appendix C: Requests for transfers of care from specialised adult services**

Transfers of care may be requested by other designated Gender Dysphoria Clinics that are commissioned against this service specification. Transfer requests must include diagnostic coding, a summary of relevant care prior to transfer, a treatment plan with recommendations for on-going care, and patient consent to sharing of information between the initiating and receiving providers; where these criteria are not fulfilled the referral will be managed as a new referral. Individuals will be offered a single ‘induction’ consultation by the receiving provider during which the diagnostic assessment and treatment plan will be reviewed and, unless there are compelling clinical reasons (these must be carefully explained to the individual), the receiving provider will continue the previously agreed care plan. The Provider will acknowledge the transfer request in writing with the referrer and individual within 14 days. Individuals accepted for transfer of care will not be re-assessed unless there are compelling clinical reasons. A consultation with the receiving Provider will be offered at an interval consistent with the individual’s treatment plan and previous care.

**Appendix D: Transfers from the Gender Identity Development Service for Children and Young People**

The Gender Identity Development Service is commissioned to provide care and support for young people up to 18 years of age.

The objective of the transfer is a purposeful, planned movement of adolescents and young adults from a young person’s service into an adult-oriented service. A well-planned transfer must focus on the needs of the individual and must provide coordinated, un-interrupted care and support to avoid negative consequences. The parents, carers and other family members will also value support, information and guidance in the process of transfer. There are therefore compelling reasons for close cooperation, communication and mutual support between the specialist team in the Gender Identity Development Service for children and young people and specialist teams in adult services.

Although the transfer to adult services will not be made until the young person is aged at least 17 years, a request for transfer of care may be made by the young person’s service to the adult service before the young person’s 17th birthday. This may be appropriate where joint working between the two services, including joint consultations with the young person, within a “lead-in” period is beneficial to ensure a timely and effective eventual transfer or to determine if a transfer to adult services is appropriate at that time.

Young people who have completed a diagnostic assessment in the young person’s service will not be re-assessed for diagnosis in the adult service. The adult service will be provided with the relevant diagnostic codes and agreed treatment plan, including the medical treatment plan if the young person is receiving endocrine interventions, and as part of the process for transfer the adult service will agree arrangements for continued prescribing with the young person’s endocrine service.

Individualised risk management procedures should be in place and agreed across both services, particularly for more vulnerable young people or those with more complex needs.

In cases where the young person fulfils the diagnosis for gender dysphoria but does not yet have a definitive treatment plan either because they are wanting to explore options more fully, or have related very complex or psychosocial issues that mean physical interventions are not yet appropriate, the process of transfer may be likely to take longer and will require ongoing collaboration and planning between the young person’s service and the adult service focused on the needs of the individual. The nature of the individualised plan will differ according to needs, but may necessitate a joint transition clinic in appropriate cases.

By the age of 18 years the different outcomes may be:

* Where a diagnosis of gender dysphoria as a consequence of gender incongruence has been made, an agreed plan for transfer to adult gender dysphoria services has been achieved; or
* Where a diagnosis of gender dysphoria as a consequence of gender incongruence has not been made, a referral to an adult gender dysphoria service for an assessment of diagnosis, or for access to specific time-limited psychological therapies; or
* Discharge from the young person’s service and no transfer or referral to adult gender dysphoria services when this is clinically appropriate.

**Appendix E: Assessment and Diagnosis**

The Provider will undertake a specialised assessment for people who may have gender dysphoria; agree with them the most appropriate diagnostic coding; and agree a treatment plan. If the diagnosis is that the individual does not have gender dysphoria as a consequence of gender incongruence, the Provider will advise the individual and referrer on alternative services that might meet the individual’s health and well-being needs.

The Provider will triage all new referrals, and assessments will be conducted according to individual need and circumstances. The majority of individuals will have two core assessment consultations; at least one of the consultations will be face-to-face. Baseline laboratory investigations and physical measurements (height; weight; blood pressure) may be requested during the assessment, if these are consistent with the individual’s treatment objectives.

*Initial assessment consultation*

This consultation will be conducted by a regulated health professional (or by a supervised trainee). Information will be collected about: the individual’s objectives for their engagement with the service; their gender identity and expression (current and historic); and basic bio-psycho-social history.

*Diagnostic and treatment planning consultation*

This consultation will be conducted by a medical practitioner or clinical or counselling psychologist (or by a supervised trainee). Information from the referrer and the initial consultation, together with any investigation results, will be reviewed and further explored with the individual. Diagnostic coding will be discussed and agreed with the individual. The individual’s treatment goals will be discussed and agreed. A general assessment of capacity to consent to treatment will be made. A written treatment plan, with indicative timelines, will be discussed and agreed with the individual and shared with the GP and referrer. The treatment plan may recommend that the individual progress to a treatment process. Other outcomes may include a recommendation to the referrer or GP that the individual be referred to other services, or that a referral should be deferred to a later date because of other health or social issues that would prevent the individual from currently benefiting from the interventions offered by the specialised service network. All outcomes will be carefully explained to the individual.

*Additional assessment consultations*

A minority of individuals have complex or additional needs such that more than two core assessment consultations may be appropriate. This may include people with co-existing complex physical or mental health problems, communication difficulties or learning difficulties. In these circumstances, the clinician must explain to the individual the reason for the proposed additional consultations. The incidence of extended consultations will be compared between providers, to identify un-warranted variation in clinical practice.

*Family members*

The Provider must not insist that the individual gives permission for family members or other people to attend appointments jointly with the individual. If a clinician advises the individual that it would be beneficial for a family member or other person to jointly attend an appointment, the reasoning must be explained to the individual, and reassurance given that a refusal to give permission will not prejudice the individual's assessment or ongoing treatment.

*Assessment of patients who have been granted a Gender Recognition Certificate*

The Gender Recognition Act 2004 enables a trans-person to apply to the Gender Recognition Panel to receive a Gender Recognition Certificate. Individuals who are granted a full Gender Recognition Certificate are considered in the eyes of the law to be of their acquired gender and they are entitled to all the rights appropriate to a person of their acquired gender.

An individual with a Gender Recognition Certificate will already have obtained a clinical diagnosis of gender dysphoria (as that is a requirement for the granting of a Gender Recognition Certificate). As such, the assessment and diagnosis element of the individual’s contact with the Provider will be adjusted to reflect the existing diagnosis of gender dysphoria.

Possession of a Gender Recognition Certificate does not in itself provide the multi-disciplinary team with the clinical information that is necessary to assess an individual’s suitability and readiness for the medical and other health interventions that are available along the NHS pathway of care. As such, individuals with a Gender Recognition Certificate will be assessed for readiness of interventions, including surgical interventions, as otherwise described in this service specification and will include the individual’s:

* Expectations of the interventions and how they will impact upon them socially and psychologically
* Health history
* Understanding of the interventions and their potential benefits, risks and limitations
* Support network and strategies for thriving after the intervention
* Plans for preparation and aftercare following intervention

**Appendix F: Physical examination**

Physical examination, other than the measurement of height, weight and blood pressure, must not be performed routinely during the assessment process. Examination of genitalia and chest is not a routine part of the assessment process. Physical examination may be recommended by the clinical team only if the individual’s clinical history suggests that physical examination is likely to result in important benefit to the individual, or is likely to reduce an important risk of harm; or as a response to a specific request by the individual. Individuals must be told that they have the right to refuse physical examination and that refusal will not affect their care with the Provider, unless omission of examination is likely to significantly compromise their safety. In rare circumstances, a refusal of examination (by any medical practitioner in any setting) may increase the clinically-relevant risk associated with medical and surgical interventions, to such a degree that it would be unethical to proceed with those interventions.

The individual’s views will be sought with regard to who shall examine them, which may include the GP, and providers will endeavour to fulfil their wishes with regard to the gender of the examining medical practitioner. Physical examination must not be performed by the medical practitioner involved in the patient’s assessment process.

The examining medical practitioner must:

* Explain in advance what the examination involves, what information it is intended to yield, and why it is clinically justified
* Ensure the examination is held in private, in a secure, quiet and calm environment
* Always offer a chaperone (this must be documented in the individual’s notes, as must an individual’s choice to decline having a chaperone present)
* Ask the individual’s preferred terms for parts of the body
* Defer examination to a later visit, allowing the individual to build a trusting relationship with the medical practitioner

*Chaperones for physical examination [[5]](#footnote-5)*

A chaperone should usually be a health professional and the examining medical practitioner must be satisfied that the chaperone will:

* Be sensitive and respect the individual’s dignity and confidentiality
* Reassure the individual if they show signs of distress or discomfort
* Be familiar with the procedures involved in a routine intimate examination
* Stay for the whole examination and be able to see what the examining medical practitioner is doing, if practical
* Be prepared to raise concerns if they are concerned about the examining medical practitioner behaviour or actions

A relative or friend of the individual is not an impartial observer and so would not usually be a suitable chaperone, but the examining medical practitioner should comply with a reasonable request to have such a person present as well as a chaperone.

If either the medical examining practitioner or the individual does not want the examination to go ahead without a chaperone present, or if either party is uncomfortable with the choice of chaperone, the examination may be delayed to a later date when a suitable chaperone will be available, as long as the delay would not adversely affect the individual’s health.

If the examining medical practitioner does not want to proceed without a chaperone present but the individual has refused to have one, the examining medical practitioner must explain their reasoning clearly, but ultimately the individual’s clinical needs must take precedence. The examining medical practitioner may wish to consider referring the patient to a colleague who would be willing to examine them without a chaperone, as long as a delay would not adversely affect the patient’s health.

**Appendix G: Named Professional’s role in treatment process**

Individuals who progress to a treatment process, and individuals accepted for direct transfer of care between specialised services, will be allocated a ‘Named Professional’ for the duration of the episode of care. This will be a regulated health professional who will act as the individual’s primary ‘point of contact’ with the service, provide basic information about interventions and the care process, and oversee and facilitate timely progress through the individual’s treatment plan, including those elements of the care pathway that are delivered by other providers. They will liaise and share information with other clinicians involved in the individual’s care with the specialised network and with the GP. With the individual’s consent, they will also deliver supportive counselling according to need.

The frequency of contact should be determined according to individual need, though usually the minimum frequency of contact will be every six months.

It will be explained to individuals why engagement with a Named Professional is essential and integral to the monitoring and management of their individual treatment plan. Providers must offer flexible access, including consultation by video communication, telephone and e-mail where this is appropriate to the individual’s circumstances, though individuals are expected to attend face-to-face consultations at least once a year during the course of their care.

There is value in maintaining continuity of care by minimising change in the person acting as Named Professional for individuals as they progress from assessment to discharge, but this may be necessary because of changing individual and service needs, or individual choice.

**Appendix H: Lead Clinician role in treatment process**

A registered medical practitioner or clinical or counselling psychologist will be appointed as ‘Lead Clinician’ for individuals who progress to a planned intervention on the NHS care pathway.

The Lead Clinician will provide oversight of each individual’s progress towards completion of their treatment plan. The Lead Clinician may be the same person as the Named Professional. The clinician providing specialised psychological therapy should not also hold the ‘Lead Clinician role.

A professional in a Lead Clinician role must demonstrate evidence of training and have at least two years’ full time or equivalent experience in specialised gender dysphoria practice, or undertake regular mentoring with, and work under the supervision, of a professional with such experience. There is value in maintaining continuity of care by minimising change in the person acting as Lead Clinician for individuals as they progress from assessment to discharge, but this may be necessary because of changing individual and service needs, or individual choice.

The Lead Clinician will initiate the interventions documented in the treatment plan and described in this service specification (some interventions require two opinions as described). All individuals who are offered a medical intervention will be given advice on smoking cessation, encouraged to take regular exercise and adopt a healthy lifestyle (so far as relevant to their circumstances).

**Appendix I: Specialised psychological interventions**

The aims of specialised psychological interventions, alone or as part of a wider multi-disciplinary network, are to:

* Provide an opportunity to access affirmative support, information, skills and resources to facilitate and adjust to psychological, physical, relational, social and practical changes and to promote wellbeing
* To advise and/or provide access to effective interventions based on psychological assessment and collaborative formulation, adapted to the needs of the person(s)
* Provide an opportunity for clarity, hope and agency in the person’s particular experience and management of gender dysphoria

The Provider will make available specific psychological interventions that are adapted to the needs of the individual based on psychological assessment and collaborative formulation.

Psychological interventions will not be offered routinely or considered mandatory, but instead with the consent of the individual and focussed on specific psychological needs. Psychological interventions will be delivered in line with those demonstrating good evidence in other areas of healthcare and in line with the guidelines of the *National Institute for Health and Care* *Excellence* where they exist.

Psychological interventions can be offered as a primary intervention, consecutively or concurrently to medical treatments, surgery or other specialised service network-based interventions where this is indicated. This includes referral for psychological interventions post-operatively, whether planned or in response to need.

Good practice for engaging in psychological interventions with transgender people has been published[[6]](#footnote-6). Providers will ensure adequate training, supervision, caseload management and support to ensure clinicians are competent and able to provide affirmative interventions.

**Appendix J: Arrangements for prescribing endocrine treatments**

Endocrine treatments may influence central nervous system function and cognition (thoughts and feelings) as well as sex-specific physical characteristics. They may augment physical interventions intended to modify secondary sex characteristics. They may mitigate the unwanted endocrine and metabolic effects of hypogonadism, which follow gonadectomy or the suppression of sex hormones produced by the body.

Endocrine and other pharmacological interventions may be recommended by a registered medical practitioner in the specialist multi-disciplinary team or the medical practitioner may decide to assume responsibility for prescribing for a time-limited period that is appropriate to the individual, before a transfer of clinical responsibility to the individual’s GP. The interventions may be appropriate where they are essential for the purpose of harm reduction, and where they are in the individual’s best interest for reducing gender dysphoria, when assisting the individual in achieving gender expression congruent with their identity and consistent with their treatment goals. It is not a requirement for access to endocrine and other pharmacological interventions to undertake a change in social role.

The recommending medical practitioner will assess the risks, benefits and limitations of pharmacological interventions for the individual, and will ensure that that the individual meets the relevant eligibility criteria set out in the *World Professional Association for Transgender Health Standards of Care (2011)*:

* Persistent, well-documented gender dysphoria
* Capacity to make a fully informed decision and to consent for treatment
* If significant medical or mental concerns are present, they must be reasonably well-controlled

They will obtain written consent to the interventions under consideration from the individual, and provide a copy of the consent to the individual and their GP.

They will provide the GP with patient-specific ‘prescribing guidance’, which will consist of a written treatment recommendation, and adequately-detailed information about necessary pre-treatment assessments, recommended preparations of medications, and advice on dosages, administration, initiation, duration of treatment, physical and laboratory monitoring, interpretation of laboratory results and likely treatment effects.

Most recommendations will be for medications to be used outside the indications approved by the *Medicines and Healthcare Products Regulatory Agency*; the *General Medical Council* advises GPs that they may prescribe ‘unlicensed medicines’ where this is necessary to meet the specific needs of the patient and where there is no suitably licensed medicine that will meet the patient’s need[[7]](#footnote-7).

GPs will be given advice on dose titration and the introduction of additional pharmacological interventions by the provider. The Provider will respond promptly to requests by GPs for advice regarding the interpretation of laboratory results and medication use.

Individuals receiving endocrine and other pharmacological interventions recommended by the Provider will have these reviewed by a medical practitioner from the specialist multi-disciplinary team at least once in twelve months. More frequent review should be provided according to clinical need, particularly after treatment initiation or following significant changes in regimen. The purpose of clinical monitoring during hormone use is to assess the degree of feminisation / masculinisation and the possible presence of adverse effects of medication.

The Lead Clinician will provide the GP with written advice when the individual is discharged. They will give advice on the individual’s future need for endocrine and other pharmacological interventions, the anticipated duration of treatment (which may be life-long), the regimen recommended for on-going use, its intended effects and possible side-effects, long-term monitoring recommendations, and how they might access further information in the future.

*Medication for masculinisation*

* Testosterone preparations (includes testosterone injections and transdermal gels)
* Medications to suppress hypothalamic-pituitary-gonadal activity and menstruation

*Medication for feminisation*

* Estradiol preparations at doses necessary to achieve serum estradiol levels typical of a pre-menopausal woman. (includes oral estradiol, and transdermal estradiol as patches and gels; transdermal estradiol preparations should be offered to people over 40; ethinylestradiol will not be recommended)
* Medications to suppress hypothalamic-pituitary-gonadal activity and endogenous testosterone release (includes gonadotropin releasing hormone analogues and 5-alpha reductase inhibitors)
* Ornithine decarboxylase inhibitors may be recommended as an adjunct to facial hair reduction interventions.

An individual being significantly overweight increases their risk of adverse effects and complications related to treatment with estradiol and medications that block the effects of testosterone. There is strong evidence that an individual’s risk of thrombosis increases as their Body Mass Index (BMI) increases. Consensus opinion amongst specialist medical practitioners is that individuals with a BMI of 40 or more should lose weight before using such hormone therapies. Whilst a BMI greater than 40 is not exclusion to this treatment, hormone therapy should only be recommended following an individualised discussion of risk, possible adverse effects and possible impacts on final treatment outcome.

There is strong evidence that an individual’s risk of thrombosis is increased if they smoke, particularly if they are treated with estradiol. Consensus opinion amongst specialist medical practitioners is that individuals who smoke should desist whilst using hormone therapies, and particularly if they are treated with estradiol. Whilst smoking is not an exclusion to access to this treatment, hormone therapy should only be recommended following an individualised discussion of risk, possible adverse effects and possible impacts on final treatment outcome.

**Appendix K: Future arrangements for prescribing and monitoring endocrine treatments**

NHS England has published guidance called “Responsibility for Prescribing Between Primary and Secondary / Tertiary Care” (2018). This guidance describes the responsibilities of all professionals involved in prescribing for patients whose care is transferred from a specialist team to primary care, and to provide support in developing shared care agreements.

In accordance with this guidance, future versions of this service specification will describe that a transfer of clinical responsibility from a Gender Dysphoria Clinic to primary care should only be considered where the individual’s clinical condition is stable or predictable, and that the Gender Dysphoria Clinic will assume and retain responsibility for providing prescriptions and for monitoring until the GP has agreed to a transfer of responsibilities through a documented shared care agreement for the individual. From then on the individual will obtain prescriptions from the GP, who will be supported by the Gender Dysphoria Clinic as appropriate to the individual’s needs.

When, in the future, the service specification is amended as described, organisations who are contracted to deliver services of a Gender Dysphoria Clinic will be engaged by NHS England in the joint formation of a phased implementation plan, including identification of resource implications.

**Appendix L: Quality indicators**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Number** | **Indicator** | **Descriptor** | **Notes** | **Evidence documents** | **Data source** | **Domain** | **CQC question** |
|  | **Clinical Outcomes - quantitative data where possible using national data need to minimise the burden** |
| **101** | % of referrals acknowledged in writing by the provider with the referrer and individual within 14 calendar days | % of referrals acknowledged in writing by the provider with the referrer and individual within 14 calendar days |   | Annual Report | HES / SSQD | 4 | Well-led, effective |
| **102** | % of referrals received where the diagnosis after assessment is either Gender Dysphoria (as per DSM-V) or Gender Incongruence (as per ICD-11 when available) | % of referrals received where the diagnosis after assessment does not fulfil the diagnostic criteria of either Gender Dysphoria (as per DMS-V) or Gender Incongruence (as per ICD-11 when available); and therefore the patient does not require services from the service |   | Annual Report | HES / SSQD | 2, 4 | Effective, caring, responsive |
| **103** | % of patients receiving more than two assessment consultations | % of patients receiving more than two diagnostic assessment consultations before a complete management plan could be made |   | Annual Report | HES / SSQD | 2, 4 | Effective, caring, responsive |
| **104** | % of patients who do not enter into the treatment programme following two assessment consultations | % of patients who do not enter into the treatment programme following two consultations |   | Annual Report | HES / SSQD | 2, 4 | Effective, caring, responsive |
| **105** | Number of patients open to the service with polycythaemia following endocrine treatment (initiated by the service) needing venesection | Number of patients open to the service with polycythaemia following endocrine treatment (initiated by the service) needing venesection |   | Annual Report | HES / SSQD | 3 | Safe, effective, caring, responsive |
| **106** | Number of patients open to the service reporting DVT/PE following endocrine treatment (initiated by the service) where action is required | Number of patients open to the service reporting DVT/PE following endocrine treatment (initiated by the service) where action is required |   | Annual Report | HES / SSQD | 3 | Safe, effective, caring, responsive |
| **107** | Number of patients open to the service with cardiovascular complications (e.g. MI or Stroke) post hormone treatment (initiated by the service)  | Number of patients open to the service with cardiovascular complications (e.g. MI or Stroke) post hormone treatment (initiated by the service)  |   | Annual Report | HES / SSQD | 3, 4 | Safe, effective, caring, responsive |
| **108** | Number of patients requesting chest reconstruction surgery who do not request hormone treatment pre-surgery | Number of patients requesting chest reconstruction surgery who do not request hormone treatment |   | Annual Report | HES / SSQD | 3 | Effective, caring, responsive |
|  | **Patient Experience**  |  |  |  |
| **201** | The service reviews the national PROM/PREM data | Providers will receive data from the national PROM/PREM data source and will review as a team and establish service development plans to continually improve the service | On line reporting tool for access by patients will be adopted by NHS England for 2019/20 | Annual Report | Self-declaration | 4 | Caring, responsive |
| **202** | Patient information | Patient information (in paper or online) is provided to all patients and includes details as listed in the service specification |   | Operational Policy | Self-declaration | 4 | caring, responsive |
|  | **Structure and Process - infrastructure requirements, staffing, facilities etc.** |  |  |  |
| **301** | There is a Clinical Lead for the service | There is a Clinical Lead in place who meets the description in the service specification |   | Operational Policy | Self-declaration | 2, 3, 4 | Well-led |
| **302** | There is a Named Professional and Lead Clinician allocated for the duration of the patients care | There is a Named Professional and Lead Clinician allocated for the duration of the patients care |   | Operational Policy | Self-declaration | 4 | Effective, caring |
| **303** | There is a system of corporate governance, including a nominated senior manager who provides guidance, oversight and accountability | There is a system of corporate governance, including a nominated senior manager who provides guidance, oversight and accountability |  | Operational Policy | Self-declaration | 5 | safe, effective, well-led |
| **304** | Patients receiving endocrine and pharmacological interventions are reviewed at least annually | Patients receiving endocrine or pharmacological interventions have these reviewed annually by a medical practitioner |   | Operational Policy | Self-declaration | 2, 3, 4 | Safe, effective, caring, responsive |
| **305** | There is an agreed patient pathway | There should be a patient pathway in place as per the service specification |   | Operational Policy | Self-declaration | 2, 3, 4, 5 | Safe, effective, caring, responsive |
| **306** | There are transition clinics in place | Arrangements exist which include joint transition clinics to ensure the transfer of care of patients from adolescence to adulthood services |   | Operational Policy | Self-declaration | 2, 4 | Safe, effective, caring, responsive |
| **307** | The team participates in clinical audit activity on an annual basis, participating in both local and national audits | The team participates in clinical audit activity on an annual basis, participating in both local and national audits |   | Operational Policy | Self-declaration | 1, 2, 3, 4 | Well-led, safe, effective, caring |

**Version Control**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Version Number** | **Date** | **Author / Approving Body** | **Status** | **Comment / Reason / Approving Body** |
| 2 | May 2019 | Gender Identity Programme Board | Approved | Addition to 2.19 to clarify referral criteria for individuals with a Gender Recognition Certificate |
| 2 | May 2019 | Gender Identity Programme Board | Approved | Addition to 2.21 “Gender Identity Healthcare Credential (Royal College of Physicians)” |
| 3 | June 2019 | Gender Identity Programme Board | Approved | Addition of (new) Appendix K that describes future arrangements for prescribing hormone treatments. Previous Appendix K re-named Appendix L.  |
| 4 | October 2022 | National Commissioning Group for Specialised, Health and Justice and Armed Forces Services | Approved | Amendment to Appendix J to describe that medical practitioner may decide to assume responsibility for prescribing for a time-limited period that is appropriate to the individual. |
| 4 | October 2022 | Medical Projects Team | Approved | References to “Clinical Commissioning Groups” changed to “Integrated Care Systems” to reflect NHS commissioning structures.References to “National Trans Health Units” removed.Amendment to 2.1.2 to refer to “sexual health services” and to remove description of role of Gender Dysphoria Clinics in regard to newly established services in primary care and sexual health settings. |

1. The revised ICD 11 refers to the wider category of 'gender incongruence' (not yet adopted). [↑](#footnote-ref-1)
2. The Royal College of Speech and Language Therapists’ “*Trans and Gender-Diverse Voice & Communication Therapy Competency Framework*” (2018) defines the recommended competency in relation to voice and communication assessment, therapy and advice for service users who identify as Trans and/or gender-diverse. [↑](#footnote-ref-2)
3. NHS England is a signatory to the “*Memorandum of Understanding on Conversion Therapy in the UK Version 2*” (2017) [↑](#footnote-ref-3)
4. Should the Gender Recognition Act 2004 be amended or repealed such that the above-mentioned requirements are removed from the legal recognition process then the criteria for access to genital surgery shall be reviewed by NHS England and changes recorded in an amended version of this service specification. [↑](#footnote-ref-4)
5. *Intimate Examinations and Chaperones;* General Medical Council; 2013 [↑](#footnote-ref-5)
6. *Guidelines and Literature Review for Psychologists Working Therapeutically with Sexual and Gender Minority Clients*; British Psychological Society; 2012 and *Guidelines for Psychological Practice With Transgender and Gender Nonconforming People*; American Psychological Association; 2015; and *Standards of Care (v7);* World Professional Association for Transgender Health; 2011 [↑](#footnote-ref-6)
7. *Advice for Doctors Treating Transgender Patients;* General Medical Council; 2016 [↑](#footnote-ref-7)